The DOI matches its Crossref record.
Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: A single center report of 8 cases
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
There is very limited data on the dose of corticosteroids used to treat DI-ALH in the published literature.
“There is very limited data on the dose of corticosteroids used to treat DI-ALH in the published literature.”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [34]
Treatment decisions are often based on experience gained from case reports or expert opinion.
“Treatment decisions are often based on experience gained from case reports or expert opinion.”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [34]
No relapses were observed after short-term immunosuppression in the studies by Rodrigues et al. and by Björnsson et al.
“No relapses were observed after short-term immunosuppression in the studies by Rodrigues et al. (infliximab and adalimumab)34 and by Björnsson et al. (infliximab).49,50”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [34]
In DI-ALH, after withdrawal of the causative agent and with institution of immunosuppression, the outcome is generally good in most cases, with a low risk of relapse or progression to chronic liver injury.
“After the withdrawal of the causative agent and with institution of immunosuppression, the outcome in DI-ALH is generally good in most cases, with a low risk of relapse or progression to chronic liver injury, as reported in different studies with heterogeneous follow-up (Table 1).14,17,34,35,50”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [34]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 23
- 10.1016/j.cgh.2012.12.025 · DOI · Paper page
- 10.1002/hep.23584 · DOI · Paper page
- 10.1097/RHU.0b013e318228bcb6 · DOI
- 10.1136/ard.2004.032821 · DOI
- 10.1002/ibd.20293 · DOI
- 10.1097/MCG.0b013e3181a745e7 · DOI
- 10.1016/j.crohns.2010.12.007 · DOI
- 10.1111/j.1365-2230.2008.03088.x · DOI
- 10.1016/j.jaad.2009.02.029 · DOI
- Poulin Y, Thérien G. Drug-induced hepatitis and lupus during infliximab treatment for psoriasis: case report and literature review. J Cutan Med Surg 2010;14:100-104.
- Saleem G, Li SC, MacPherson BR, Cooper SM. Hepatitis with interface inflammation and IgG, IgM, and IgA anti-double-stranded DNA antibodies following infliximab therapy: comment on the article by Charles et al. Arthritis Rheum 2001;44:1966-1968.
- 10.1016/j.crohns.2012.01.017 · DOI
- 10.1097/01.mib.0000246783.75753.9f · DOI
- 10.1007/s10067-005-0169-y · DOI
- 10.1111/j.1365-2230.2006.02086.x · DOI
- 10.1007/s10067-006-0253-y · DOI
- 10.1002/ibd.20230 · DOI
- 10.1007/s11739-009-0342-4 · DOI
- 10.2165/11586210-000000000-00000 · DOI
- 10.1007/s10620-011-1748-1 · DOI
- 10.1016/j.gcb.2010.01.016 · DOI
- 10.1016/j.jhep.2012.11.010 · DOI
- 10.1016/j.jhep.2011.02.024 · DOI · Paper page
Cited by
Sorted by citations
Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines
Devarbhavi, H., Aithal, G., Treeprasertsuk, S., Takikawa, H., Mao, Y., Shasthry, S. M., Hamid, S., Tan, S. S., Philips, C. A., George, J., et al. (2021) · Hepatology International · doi:10.1007/s12072-021-10144-3 · Cited by 181
Andrade, R. J., Aithal, G. P., de Boer, Y. S., Liberal, R., Gerbes, A., Regev, A., Terziroli Beretta-Piccoli, B., Schramm, C., Kleiner, D. E., De Martin, E., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.033 · Cited by 166
Biologic and checkpoint inhibitor‐induced liver injury: a systematic literature review
Shah, P., Sundaram, V., & Björnsson, E. (2020) · Hepatology Communications · doi:10.1002/hep4.1465 · Cited by 64
Functional heterogeneity of CD4+ T cells in liver inflammation
Muscate, F., Woestemeier, A., & Gagliani, N. (2021) · Seminars in Immunopathology · doi:10.1007/s00281-021-00881-w · Cited by 32
Metadata
- Authors
- Rodrigues, S.
- Venue
- World Journal of Gastroenterology
- Publisher
- Baishideng Publishing Group Inc.
- Published
- 2015
- Volume
- 21
- Issue
- 24
- Pages
- 7584
- ISSN
- 1007-9327
- Cited by
- 97
- References
- 0
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
